复宏汉霖(02696.HK)：欧盟委员会批准斯鲁利单抗注射液新增适应症：联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗

智通财经06-25

【复宏汉霖(02696.HK)：欧盟委员会批准斯鲁利单抗注射液新增适应症：联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗】智通财经APP讯，复宏汉霖(02696.HK)发布公告，近日，欧盟委员会(European Commission, EC)已批准本公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2646797048?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-25 18:06","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2646797048","market":"us","top_or_hot":-1,"title":"复宏汉霖(02696.HK)：欧盟委员会批准斯鲁利单抗注射液新增适应症：联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗","media":"智通财经","content":"<div>\n<p>【复宏汉霖(02696.HK)：欧盟委员会批准斯鲁利单抗注射液新增适应症：联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗】智通财经APP讯，复宏汉霖(02696.HK)发布公告，近日，欧盟委员会(European Commission, \n\nEC)已批准本公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696.HK)：欧盟委员会批准斯鲁利单抗注射液新增适应症：联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696.HK)：欧盟委员会批准斯鲁利单抗注射液新增适应症：联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-25 18:06 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【复宏汉霖(02696.HK)：欧盟委员会批准斯鲁利单抗注射液新增适应症：联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗】智通财经APP讯，复宏汉霖(02696.HK)发布公告，近日，欧盟委员会(European Commission, \n\nEC)已批准本公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EEA","symbol_name":"European Equity Fund","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2646797048","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646797048","pubTimestamp":1782382017,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【复宏汉霖(02696.HK)：欧盟委员会批准斯鲁利单抗注射液新增适应症：联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗】智通财经APP讯，复宏汉霖(","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"EEA":"European Equity Fund"},"translate_title":"Henlius (02696.HK): The European Commission approved the new indication of Slulizumab injection: combination chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) who are not surgically resectable","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EEA":1},"content_text":"【复宏汉霖(02696.HK)：欧盟委员会批准斯鲁利单抗注射液新增适应症：联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗】智通财经APP讯，复宏汉霖(02696.HK)发布公告，近日，欧盟委员会(European Commission, \n\nEC)已批准本公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)( \n\n斯鲁利单抗)新增适应症：斯鲁利单抗联合卡铂和白蛋白紫杉醇适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗(本次新增适应症)。此次获批意味着斯鲁利单抗本次新增适应症在所有欧盟成员国及冰岛、列支敦士登和挪威(各自为欧洲经济区(EEA)国家)获得批准。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646797048","isCrawlerRequest":true}